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Abstract 
We investigated the effect of GLPs on glucose uptake in isolated rat adipocytes. GLP-l(7-36)amide significantly enhanced glucose 
uptake in the presence of 1 nM insulin. GLP-l(7-36)amide at 15 nM increased glucose uptake maximally by 56.4% as compared with 1 
nM insulin alone (P < 0.01). In contrast, with less than 1 nM insulin or without insulin GLP-l(7-36)amide showed no effect on glucose 
uptake. Full-sequence GLP-l(1-37) at 15 nM in the presence of 1 nM insulin increased glucose uptake by 24.6% as compared with 1 nM 
insulin alone (P < 0.05). GLP-2 showed no effect on glucose uptake. Further, we examined the effect of GLP-l(7-36)amide on cAMP 
content in isolated rat adipocytes. Insulin at 1 nM caused a significant decrease of cAMP content. The combination of 15 nM 
GLP-l(7-36)amide and 1 nM insulin caused a further eduction of cAMP content. These data indicate that GLP-l(7-36)amide possesses 
augmentative effects on insulin action in isolated rat adipocytes. Furthermore, it is suggested that the stimulatory effect of GLP-l(7- 
36)amide occurs through the reduction of intracellular cAMP content. 
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1. Introduction 
Glucose ingestion induces a considerably greater eleva- 
tion in plasma insulin level compared with an intravenous 
glucose load. This augmented /3-cell response to an oral 
glucose challenge was suggested to be the result from the 
gut hormones that potentiate mainly glucose-induced in- 
sulin secretion [1-3]. This effect, referred to as the incretin 
effect, has been attributed to several insulinotropic pep- 
tides from intestinal extracts. Of these peptides, GLP- l (7-  
36)amide is the most potent insulinotropic peptide [4-6]. 
Pancreatic r-cell have the specific receptor for GLP-I(7- 
Abbreviations: GLP-l(7-36)amide, glucagon-like peptide-l(7- 
36)amide. 
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36)amide that is coupled to the production of cAMP and 
activation of cAMP-dependent protein kinase. The eleva- 
tion in intracellular cAMP levels is required to mediate the 
incretin effect of the hormone [7,8]. So far, the research in 
GLP-l(7-36)amide have been exclusively focused on its 
incretin effect. 
Recent studies suggested that the infusion of GLP- l (7 -  
36)amide improves insulin sensitivity in patients with 
IDDM as well as NIDDM [9]. It has been reported that the 
specific receptor for GLP-l(7-36)amide is present in hu- 
mans as well as rat adipose tissue [10,11]. To clarify 
whether this peptide enhances insulin action of target 
tissue, we investigated the effect of GLPs on glucose 
uptake in isolated rat adipocytes. Furthemao~, since it has 
been reported that cAMP levels modulate insulin-stimu- 
lated glucose uptake [12,13], we examined the effect of 
GLP-l(7-36)amide on intracellular cAMP content. 
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2. Materials and methods 
2.1. Materials 
Porcine insulin, dimethyl sulfoxide, 2-deoxy-D-glucose, 
phloretin, 3-isobutyl-1 methyl-xanthine (IBMX) and 
forskolin were obtained from Sigma (St. Louis, MO). 
Collagenase was obtained from Worthington (Freehold, 
NJ). [3H]2-deoxy-D-glucose and bovine serum albumin 
(BSA) fraction V were obtained from Daiich (Tokyo). 
GLP-l(7-36)amide, GLP-I(1-37) and GLP-2 were pur- 
chased from Peninsula (Belmont, CA). cAMP EIA kits 
were obtained from Amersham International (Aylesbury, 
Buckinghamshire, UK). All other reagents of analytical 
grade were from standard suppliers. 
2.2. Preparation of isolated rat adipocytes 
Adipocytes were isolated from epididymal fat pads 
removed from male Sprague-Dawley rats (200 ~ 250 g) 
fed ad libitum using the co]lagenase digestion method. The 
fat pads were cut into small pieces and incubated at 37°C 
for 30 min incubation medium consisting of 130 mM 
NaC1, 4.7 mM KC1, 2.5 mM CaCI 2, 2.5 mM NaH2PO 4, 
1.2 mM MgSO 4, 1% BSA, 10 mM Hepes-NaOH (pH 7.4). 
The medium was further fortified with 3% BSA, 2.5 mM 
glucose and 0.1% collagenase. The digested tissue were 
filtered through a double-layered nylon stocking and resul- 
tant cell suspension was washed four times by suspension 
and floatation with the above non-fortified incubation 
medium. 
2.3. Measurement of hexose uptake 
Hexose uptake into the cells was determined by the oil 
floatation technique described Gliemann et al. with slight 
modifications [14]. Typically, adipocytes from 5 g of 
adipose tissue were used for each treatment. The 
adipocytes, which were pretreated with GLP- l (7-  
36)amide, GLP-l(1-37) and GLP-2 in the presence or 
absence of insulin at 37°C for 30 min, were incubated with 
the further addition of 0.15 /~Ci [3H]]2-deoxy-D-glucose 
(2-deoxyglucose final concentration f 48 /~M) for 3 min. 
After the termination of hexose uptake by the addition of 
0.3 mM phloretin, 0.25 ml aliquots were pipetted into 
microfuge tube containing 0.14 ml of silicon oil. The tube 
were centrifuged immediately with a microcentrifuge at
12000 rpm for 60 s and then cut through the oil layer for 
determination f radioactivity in the adipocytes pellets. 
2.4. Measurement of cAMP content 
In the presence of 0.25 ~ IBMX, be  adip~y~s 
treated with GLP-l(7-36)amide or forskolin for 30 min as 
above, were further incubated with or without 1 nM insulin 
for 10 rain at 37°C. After incubation, the cell suspension i
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Fig. 1. Effect of insulin at the concentrations from 10 -~z to 10 -7 M on 
glucose uptake in isolated rat adipocytes. Data are means-t-SE of three 
separate xperiments. 
microfuge tube was boiled in a water bath for 5 min to 
denaturalize proteins. The tube were centrifuged at 12 000 
rpm for 5 min and then cut through the intermediate layer. 
The cAMP content of the samples was measured with 
cAMP EIA system. 
2.5. Statistical analysis 
Data are presented as means + SE. Differences among 
groups were tested by analysis of variance. P < 0.05 was 
considered statistically significant. 
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Fig. 2. Effect of GLP-l(7-36)amide at the concentations from 0.15 to 
150 nM on glucose uptake in the presence of 1 nM insulin in isolated rat 
adipocyte. Data are means + SE of two separate xperiments. 
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3. Resu l ts  
3.1. Effects of GLP-1(7-36)amide on glucose uptake in 
isolated rat adipocytes 
Insulin increased glucose uptake in a dose-response 
manner from 10 -11 to 10 -7 M (Fig. 1). The EDs0 was 
observed at a concentration f about 10 -9 M, and thus we 
adopted the concentration of 1 nM insulin to investigate 
the effect of GLPs on glucose uptake. GLP-l(7-36)amide 
significantly enhanced glucose uptake in the presence of 1 
nM insulin. The significant increment of glucose uptake by 
GLP-l(7-36)amide was observed at the concentrations 
from 1.5 to 150 nM (Fig. 2). GLP-l(7-36)amide at 15 nM 
maximally increased glucose uptake by 56.4% as com- 
pared with 1 nM insulin alone. 
Next, we investigated the effect of GLP-l(7-36)amide 
on glucose uptake in the presence of low insulin concentra- 
tions. In the presence of less than 1 nM insulin, GLP-l(7- 
36)amide did not modulate glucose uptake (Fig. 3). Fur- 
thermore, in the absence of insulin, GLP-l(7-36)amide 
did not enhance glucose uptake at any concentrations 
examined (Fig. 4). 
GLP-l(1-37) at 15 nM in the presence of 1 nM insulin 
increased glucose uptake by 24.6% as compared with 1 
nM insulin alone (Fig. 5A). GLP-2 at 15 nM showed no 
effect on glucose uptake (Fig. 5B). 
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Fig. 4. Effect of GLP-l(7-36)amide atthe concentrations from 1.5 to 150 
nM on glucose uptake in the absence of insulin in isolated rat adipocyte. 
Data are means + SE of 3 determinations. 
GLP-l(7-36)amide at 15 nM as well as I nM insulin 
caused a significant decrease in cAMP content. The simul- 
taneous treatment of 15 nM GLP-l(7-36)amide and 1 nM 
insulin caused a further reduction of cAMP content. 
Forskolin significantly increased cAMP content (Table l). 
3.2. Effect of insulin, GLP-l(7-36)amide and forskolin on 
intracellular cAMP content in isolated rat adipocytes 4. D iscuss ion  
To investigate the relationship between these peptides 
and cAMP, intracellular cAMP content was determined. 
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Fig. 3. Effect of GLP-l(7-36)amide (G) on glucose uptake in the 
presence oflow insulin concentrations from 0.01 to 1 nM in isolated rat 
adipocyte. Data are means +SE of 6 determinations. 
In this study, we examined whether GLPs modulate 
glucose uptake in isolated rat adipocytes. GLP-l(7- 
36)amide significantly enhanced insulin-stimulated glucose 
uptake in isolated rat adipocytes and its effect required the 
presence of at least 1 nM insulin, which corresponds to the 
postprandial insulin level of obese subjects. Furthermore, it 
is conceivable that GLP-l(7-36)amide nhances glucose 
uptake into adipocytes after meals in the presence of 
considerably high insulin level partly mediated by its 
incretin effect. Indeed, the infusion of GLP-l(7-36)amide 
at pharmacological concentrations to humans has been 
shown to stimulate postprandial insulin secretion, decrease 
glucagon release, and increase glucose utilization [9,15,16]. 
In contrast, with less than 1 nM insulin or without insulin, 
GLP-l(7-36)amide did not enhance glucose uptake. Tak- 
ing these results into consideration, GLP-l(7-36)amide 
does not seem to enhance glucose uptake in the fasting 
insulin level. It is recently reported that GLP-1 (7-36)amide 
alone failed to affect glycogenesis n rat skeletal muscle 
[17]. As above discussed, GLP-l(7-36)amide appears to 
require the presence of insulin to exert its insulin like 
action. The maximally augmented glucose uptake by GLP- 
l(7-36)amide was observed at a concentration of 15 nM 
GLP-l(7-36)amide. The increment of glucose uptake is 
comparable with the glucose uptake by 10 nM insulin, 
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which corresponds to a concentration as high as about 
1400 /xU/ml. Thus, GLP-l(7-36)amide possesses 
insulin-sparing action. Although GLP-2 at 15 nM showed 
no effect on glucose uptake, full-sequence GLP-l(1-37) 
increased glucose uptake by 24.6% as compared with 1 
nM insulin alone. Full-sequence GLP-l(1-37) is com- 
pletely conserved among the mammalian species [18]. This 
remarkably high degrees of conservation suggest that 
GLP-l(1-37) may have a significant biological function. 
Although we previously reported that GLP-l(1-37) had no 
effect on insulin secretion with the perfused rat pancreas 
[19], another eported that supra physiological concentra- 
tion of GLP-l(1-37) stimulates insulin release from iso- 
lated rat pancreas [20]. In this study, we have clarified that 
full-sequence GLP-l(1-37) also enhances insulin-simu- 
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Fig. 5. A. Effect of 15 nM GLP-l(1-37) on glucose uptake in the 
presence of insulin in isolated rat adipocyte. Data are means + SE of five 
separate experiments. B. Effect of 15 nM GLP-2 on glucose uptake in the 
presence of insulin in isolated rat adipocyte. Data are means + SE of 6 
determinations. 
Table 1 
cAMP production (fmol/microfuge tube) in isolated rat adipocytes after 
incubation with insulin, GLP-l(7-36)amide and forskolin in the presence 
of 0.25 mM IBMX 
Peptides cAMP (n) 
none 1322+73 (8) 
insulin (1 nM) 910+90 a (8) 
GLP-l(7-36)amide (15 nM) 725 + 154 a (6) 
insulin (1 nM)+ GLP-l(7-36)amide (15 nM) 487 _+ 53 b (8) 
forskolin (10/xM) 5167 + 527 (6) 
a p < 0.01 vs. none. 
P < 0.01 vs. 1 nM insuline alone. 
lated glucose uptake in isolated rat adipocytes. Compared 
with GLP-l(7-36)amide, GLP-l(1-37)reaches approxi- 
mately 50% of the maximal glucose uptake caused by 
GLP-l(7-36)amide. These effect of GLP-l( I -37) may be 
due to degradation of the peptide to the truncated form. 
Altematively, the stimulatory effect of GLP-l(1-37) may 
act on its own receptor, since GLP-l(1-37) dose not 
displace the binding of GLP-l(7-36)amide in rat 
adipocytes [10]. 
It is reported that the postprandial plasma levels of 
GLP-l(7-36)amide are about 40 pM in humans [21]. In 
this study, the concentration of GLP-l(7-36)amide that 
significantly enhances glucose uptake in the presence of 1 
nM insulin is observed from 1.5 nM, which corresponds to
30 times higher than that of postprandial plasma levels in 
humans. The high concentration of insulin as well as 
GLP-l(7-36)amide in this study may be due to the insen- 
sitivity of the cell surface by the collgenase method. 
Indeed, glucose uptake by 0.1 nM insulin alone is little 
augmentative (Figs. 1 and 3). 
Recent studies demonstrated that the elevation of intra- 
cellular cAMP level inhibits insulin-stimulated glucose 
uptake in rat adipocytes and cultured cell [12,13]. There- 
fore, we investigated the effect of GLP-l(7-36)amide on 
intracellular cAMP content. As shown in Table 1, insulin 
at 1 nM significantly decreased cAMP content. The combi- 
nation of 15 nM GLP-l(7-36)amide and 1 nM insulin 
caused an additive reduction of cAMP content. It has been 
clarified that GLP-l(7-36)amide nhances insulin-stimu- 
lated glucose uptake accompanied by a further eduction of 
intracellular cAMP content. The elevated levels of intra- 
cellular cAMP induce phosphorilated Glut 4 in rat 
adipocytes [22,23]. Increased Glut 4 phosphorilation of 
plasma membrane inhibits insulin-stimulated glucose up- 
take without any change in the cellular distribution of Glut 
4 or the translocation from the intracellular pool to the 
plasma membrane [22,23]. In contrast, insulin treatment 
resulted in significant dephosphorilation f plasma mem- 
brane Glut 4, which has a higher intrinsic activity than the 
phosphorilated Glut 4 [23,24]. Therefore, the acute stimula- 
tory effect of GLP-l(7-36)amide may be mediated by a 
further increment of dephosphorilated Glut 4 in plasma 
membrane through the reduction of intracellular cAMP 
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content. Thus, GLP- l (7 -36)amide  may well be implicated 
in the physiological control of  glucose homeostasis, not 
only by acting as an incretin, but also by promoting 
glucose disposal into peripheral tissues. 
In conclusion, GLP- l (7 -36)amide  significantly in- 
creases glucose uptake in the presence of  1 nM insulin and 
its acute stimulatory effect may occur through a reduction 
of intracellular cAMP content in rat adipocytes. 
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